Akero Therapeutics Inc (NASDAQ:AKRO) saw a downside of -5.24% to close Friday at $45.92 after subtracting -$2.54 on the day. The 5-day average trading volume is 986,000 shares of the company’s common stock. It has gained $53.00 in the past week and touched a new high 2 times within the past 5 days. An average of 1,018,730 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 726,984.
AKRO’s 1-month performance is -3.43% or -$1.62 on its low of $45.87 reached on 09/22/23. The company’s shares have touched a 52-week low of $25.21 and high of $58.38, with the stock’s rally to the 52-week high happening on 06/13/23. YTD, AKRO has lost -16.20% or -$8.88 and has reached a new high 3 times. However, the current price is down -21.34% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
AKRO stock investors last saw insider trading activity on Sep 19.Cheng Andrew (President and CEO) most recently sold 25,000 shares at $49.77 per share on Sep 01. This transaction cost the insider $1,244,248. Chief Development Officer, Yale Catriona, sold 5,745 shares at a price of $49.99 on Aug 28. Then, on Aug 01, President and CEO Cheng Andrew sold 25,000 shares at a price of $43.15 per share. This transaction amounted to $1,078,867.
Valuation Metrics
AKRO stock has a beta of -0.90. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 4.14.
Akero Therapeutics Inc’s quick ratio for the period ended June 29 was 29.78, with the current ratio over the same period at 29.78. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.04, while the total debt to equity was 0.04.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 11.84% to -$31.08 million, while revenue of -$25.83 million was 16.89% off the previous quarter. Analysts expected AKRO to announce -$0.63 per share in earnings in its latest quarter, but it posted -$0.6, representing a 4.80% surprise. AKRO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 47.37 million, with total debt at $25.93 million. Shareholders hold equity totaling $55.6 million.
Let’s look briefly at Akero Therapeutics Inc (AKRO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 29.11% to suggest the stock is trending oversold, with historical volatility in this time period at 42.95%.
The stock’s 5-day moving average is $49.31, reflecting a -12.10% or -$6.32 change from its current price. AKRO is currently trading -2.11% above its 20-day SMA, +2.20% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +1.30% and SMA200 by+4.32%.
Stochastic %K and %D was 11.89% and 30.91% and the average true range (ATR) pointed at 2.12. The RSI (14) points at 37.72%, while the 14-day stochastic is at 0.63% with the period’s ATR at 2.04. The stock’s 9-day MACD Oscillator is pointing at -2.32 and -2.17 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Akero Therapeutics Inc (NASDAQ: AKRO), Cantor Fitzgerald launched coverage with an Overweight rating.
